Value of Transcutaneous Bilirubin Devices

Launched by ASSIUT UNIVERSITY · Jan 22, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at a new way to measure bilirubin levels in newborns with jaundice. Jaundice is a common condition in babies where their skin and eyes can turn yellow due to high levels of bilirubin, a substance produced when the body breaks down red blood cells. The study will compare two methods of checking bilirubin levels: using a special device that measures it through the skin (transcutaneous bilirubin devices) versus taking a blood sample (serum bilirubin). The aim is to see which method is more effective for monitoring jaundice in newborns.

To participate in this study, babies need to be between 0 and 28 days old, born between 35 and 42 weeks of pregnancy, and weigh more than 2 kilograms at birth. However, babies who are very sick, have certain serious birth defects, skin diseases, or have received specific treatments like phototherapy or exchange transfusions will not be eligible. If your baby qualifies and participates, the study will involve simple, non-invasive tests to help understand how well the skin device works compared to traditional blood tests. This research could help improve care for babies with jaundice in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • They were born between 35 and 42 weeks of gestation, had a birth weight of more than 2 kg, and were aged between 0 days and 28 days
• Exclusion Criteria:
• • Exclusion criteria are severely ill neonates, neonates with a lethal congenital malformation, and or had skin disease, had received phototherapy before, and received exchange transfusion.